Mixed
Combining incretin-based obesity medications (semaglutide/tirzepatide) with moderate lifestyle modification (150 min/week aerobic + 2 days resistance) yields sustainable weight loss and health benefits, making intensive behavioral therapy and strict caloric restriction redundant.
If you are prescribed semaglutide or tirzepatide, you do not need to follow a strict diet or exercise for hours every day. Aim for 150 minutes of moderate walking per week and two days of strength training. This moderate approach is sufficient to maintain weight loss and health benefits alongside your medication, whereas intensive protocols are likely unnecessary and harder to sustain.
Moderate calorie restriction and, at least 150 minutes of moderate-intensity aerobic exercise and two sessions of muscle-strengthening activities per week may be more achievable and appropriate goals for sustainable weight loss in most patients on pharmaceutical obesity treatment.
Why this rating
Based on a perspective article citing multiple high-impact RCTs (STEP, SURMONT series), though not a primary trial itself.
Source
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity
Riccardo Dalle Grave · Diabetes Metabolic Syndrome and Obesity · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →